Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | RGS12 | O14924 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25887361 | 0.73 | — | — | |
| SCHEMBL5973948 | 0.73 | — | — | |
| SCHEMBL27568717 | 0.73 | — | — | |
| SCHEMBL18015608 | 0.71 | — | — | |
| SCHEMBL17471633 | 0.71 | TDP1 (0.32) | TDP1KDM4EMEN1ALDH1A1POLB | |
| SCHEMBL23572369 | 0.71 | — | — | |
| SCHEMBL11178841 | 0.71 | — | — | |
| SCHEMBL22000765 | 0.69 | TDP1 (0.30) | TDP1 | |
| SCHEMBL18870524 | 0.69 | — | — | |
| SCHEMBL24013613 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2879675-B1 | COMPOUNDS AND METHODS FOR TARGETING HSP90 | UNIV DUKE (US) | 2019-11-13 | — | — | EP | claimed |
| WO-2016205551-A2 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | WO | claimed |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-02-12 | — | — | US | disclosed |
| US-12359208-B2 | Thermal control of T-cell immunotherapy through molecular and physical actuation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4565684-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | National University Corporation Hokkaido University (JP) | 2025-06-11 | — | — | EP | disclosed |
| US-12220423-B2 | Compounds, derivatives, and analogs for cancer | HYGIA PHARMACEUTICALS, LLC (US) | 2025-02-11 | — | — | US | disclosed |
| US-20250018031-A1 | PEPTIDE VACCINES AND PEMBROLIZUMAB FOR TREATING BREAST CANCER | ONCOPEP INC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240376490-A1 | SYNTHETIC MAMMALIAN SIGNALING CIRCUITS FOR ROBUST CELL POPULATION CONTROL | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2024-11-14 | — | — | US | disclosed |
| US-12059463-B2 | Peptide vaccines and pembrolizumab for treating breast cancer | ONCOPEP, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-11999964-B2 | Synthetic mammalian signaling circuits for robust cell population control | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2011063421-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011034954-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011031865-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010117668-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2010114768-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100173934-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | BURKE GREGORY P | 2010-07-08 | — | — | US | disclosed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | TFAM, FIS1, TUFM | TDP1 854/4885KDM4E 2587/4885MEN1 3840/4885 |
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | TDP1 3915/4885KDM4E 792/4885MEN1 1499/4885 |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | TDP1 2269/4885KDM4E 3012/4885MEN1 2702/4885 |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | XBP1, MCL1, CD81 | TDP1 2920/4885KDM4E 955/4885MEN1 2034/4885 |
| US-20100173934-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | TUBB6, TUBB3, TUBB1 | TDP1 1343/4885KDM4E 3372/4885MEN1 1998/4885 |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | CCR9, IDO1, CCR10 | TDP1 3432/4885KDM4E 1044/4885MEN1 4615/4885 |
| US-12220423-B2 | Compounds, derivatives, and analogs for cancer | KRAS, PIK3CA, PIK3CD | TDP1 2827/4885KDM4E 1417/4885MEN1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.